Files
Document type
ArticleVersion
Accepted versionPublication date
All rights reserved
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/125750
Precision medicine based in epigenomics: the paradigm of carcinoma of unknown primary
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Epigenetic alterations are a common hallmark of human cancer. Single epigenetic markers are starting to be incorporated into clinical practice; however, the translational use of these biomarkers has not been validated at the 'omics' level. The identification of the tissue of origin in patients with cancer of unknown primary (CUP) is an example of how epigenomics can be incorporated in clinical settings, addressing an unmet need in the diagnostic and clinical management of these patients. Despite the great diagnostic advances made in the past decade, the use of traditional diagnostic procedures only enables the tissue of origin to be determined in ∼30% of patients with CUP. Thus, development of molecularly guided diagnostic strategies has emerged to complement traditional procedures, thereby improving the clinical management of patients with CUP. In this Review, we present the latest data on strategies using epigenetics and other molecular biomarkers to guide therapeutic decisions involving patients with CUP, and we highlight areas warranting further research to engage the medical community in this unmet need.
Subject
Subject (English)
Citation
Citation
MORAN, Sebastian, et al. Precision medicine based in epigenomics: the paradigm of carcinoma of unknown primary. Nature Reviews Clinical Oncology. 2017. Vol. 14, num. 11, pags. 682 -694. ISSN 1759-4774. [consulted: 18 of August of 2026]. Available at: https://hdl.handle.net/2445/125750